Immune Thrombocytopenia: Durable Responses Noted With Eltrombopag Plus Pulsed Dexamethasone
More than half of evaluable patients who received eltrombopag and pulsed dexamethasone achieved the study’s primary end point.
Thrombotic Disorders
THROMBOTIC DISORDERS
FEATURE
LATEST ARTICLES
Splenomegaly May Be a Negative Prognostic Factor in Essential Thrombocythemia and Polycythemia Vera
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
Rivaroxaban for Children With Acute Venous Thromboembolism
Researchers assessed the efficacy of rivaroxaban in comparison with other standard anticoagulants in children with acute venous thromboembolism.
Time of Day for Taking Warfarin Does Not Matter
Morning or evening administration makes no difference on time outside target INR range
Peripherally Inserted Central Catheters May Increase Venous Thromboembolism Risk in Children
Researchers compared the incidence of venous thromboembolism between children with peripherally inserted central catheters and children with tunneled lines.
Thromboembolic Disorder Treatments
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Bomedemstat Receives Fast Track Status for Essential Thrombocythemia
The FDA has granted Fast Track designation to bomedemstat (IMG-7289; Imago BioSciences) for the treatment of essential thrombocythemia, a myeloproliferative disorder characterized by high platelet counts.
Elderly Patients With Immune Thrombotic Thrombocytopenic Purpura at Increased Risk for Mortality
Elderly patients with immune thrombotic thrombocytopenia purpura often have atypical presentation, which can delay diagnosis and treatment.
Avatrombopag Designated Orphan Drug for Chemo-Induced Thrombocytopenia
The FDA has granted Orphan Drug designation to avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia, a complication that may lead to chemotherapy dose delays and regimen changes.
Metabolic Syndrome May Up Risk for VTE Recurrence After DVT
Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
Diagnosis and Management of Thrombocytopenia in Pregnancy
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
Blood Type as a Predictor of Response to Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura
Of patients with ADAMTS13 deficiency, those who had type O blood underwent fewer therapeutic plasma exchange procedures compared with patients with type A or B blood.
Caplacizumab Safe, Efficacious With Exacerbation of Acquired Thrombotic Thrombocytopenic Purpura
Researchers evaluated the safety and efficacy of open-label caplacizumab in patients who experienced disease exacerbation during blinded treatment.
Two Easily Measured Biomarkers Could Predict Hemorrhage in Thrombocytopenia
C-reactive protein and urine albumin/creatinine ratio were associated with increased risk of bleeding in patients with thrombocytopenia due to hematologic malignancy.
Addition of Aspirin to Direct-Acting Oral Anticoagulation May Increase Bleeding Risk
Adding aspirin to direct-acting oral anticoagulant therapy without a clear indication may increase bleeding risk without decreasing thrombotic risk.
Eltrombopag May Be Noninferior to Intravenous Immunoglobulin for Presurgery Platelet Count Boost
Of patients receiving eltrombopag, 78.9% reached platelet count targets, compared with 61.1% of patients receiving intravenous immunoglobulin.
Rivaroxaban May Be a Feasible Treatment Option for Thromboembolism in Children
Most individual pharmacokinetic parameter values fell within the expected range irrespective of dosage, VTE outcome, and bleeding events.
Relapse Delayed But Not Prevented With Rituximab for Immune TTP
Patients treated with rituximab experienced improved relapse-free survival at 1 and 3 years but not 5 years after treatment compared with patients receiving corticosteroids alone.
Does Real-World Evidence Support Apixaban Use in Cancer-Related Venous Thromboembolism?
Researchers assessed clinical outcomes with apixaban, low-molecular-weight heparin, and warfarin to treat venous thromboembolism in patients with cancer.
Characterizing Intracranial Hemorrhage Among Patients With Immune Thrombocytopenia
Patients who were older than 65 years, female, or hospitalized in the northeastern United States experienced increased incidence of intracranial hemorrhage.
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms
Vitamin K antagonist treatment was found to decrease splanchnic vein thrombosis recurrence in patients with myeloproliferative neoplasms.
Venous Thromboembolism Outcomes in Patients With Autoimmune Disorders
Researchers found no significant difference in venous thromboembolism recurrence rates between patients with and without autoimmune disorders.
Testosterone Therapy Associated With Increased Risk for Venous Thromboembolism
Risk for venous thromboembolism was increased more than 2-fold for men with and without hypogonadism who received testosterone therapy.
Treating Venous Thromboembolism in Patients With Cancer: 2019 Clinical Practice Guidelines
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Mental Health Impairment in Acute Thrombotic Thrombocytopenic Purpura
At a median follow-up of 36 months, patients with acute thrombotic thrombocytopenic purpura displayed impaired quality of life compared with the general population.
FDA Approves Earlier Use of Nplate in Immune Thrombocytopenia
The FDA has approved the supplemental Biologics License Application for Nplate (romiplostim; Amgen) to expand treatment to newly diagnosed adult patients with immune thrombocytopenia.
Study Compares Anticoagulants for Antiphospholipid Syndrome
Authors find rivaroxaban not noninferior to vitamin K antagonists for secondary thromboprophylaxis
Risk for Pulmonary Embolism Elevated for up to 18 Weeks After Surgery
Current guidelines recommend 5 weeks of postoperative prophylactic anticoagulation, but a new study suggests the duration of this treatment ought to be extended.
Rivaroxaban May Be the Best Strategy for Deep Vein Thrombosis Prevention in Total Knee Replacement
A review and meta-analysis of 25 randomized controlled trials showed that single-agent treatment strategies were generally more effective than combination strategies.
Analysis of Thrombotic Events in Patients Receiving Ibrutinib
Researchers found a low incidence of thrombotic events in patients receiving ibrutinib, though some patients still experienced bleeding.
Few Differences Found in Outcomes With Various Venous Thromboembolism Prophylaxis Protocols
Researchers found that most instances of venous thromboembolism occurred while patients were receiving prophylaxis.
Efficacy of Splenectomy Following Treatment Failure in Immune Thrombocytopenic Purpura
Splenectomy is often administered as third- or fourth-line therapy, but earlier administration may mitigate treatment-related complications.
Risk of Stroke Following an Episode of Acute TTP Seen With Low ADAMTS13 Activity
Stroke occurred in no patients with normal ADAMTS13 activity but did occur in 27.6% of patients with ADAMTS13 activity below 70%, the cutoff for normal activity.
Long-Term Venous Thromboembolism Risk Following Blood or Marrow Transplantation for Non-Hodgkin Lymphoma
Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
Low-Intensity Warfarin Did Not Meet Noninferiority for Preventing VTE or Death in GIFT Trial
Researchers assessed the efficacy of a target international normalized ratio of 1.8 compared with the standard of 2.5 for thromboprophylaxis following arthroplasty.
The Role of Vitamin K Antagonists in Managing Thrombosis in Myeloproliferative Neoplasms
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
New Score For Predicting VTE Risk in Multiple Myeloma Outperforms Current Guidelines
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
Investigation of the Causes of Extreme Thrombocytosis
Common causes of extreme thrombocytosis differed in inpatient and outpatient settings, according to a review of 44,490 patient records.
Thrombopoietin Agonists Offer Best Efficacy and Safety in Persistent Adult Immune Thrombocytopenia
Eltrombopag and romiplostim demonstrated superior response compared with rituximab for persistent adult immune thrombocytopenia.
Efficacy and Safety of Direct Oral Anticoagulant Therapy for Venous Thromboembolism
Rates of recurrence and bleeding were similar between the 3 treatments assessed, but rivaroxaban demonstrated lower mortality rates.
Guideline Update for Venous Thromboembolism Prophylaxis in Patients With Cancer
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Clinical Benefit of Oral Anticoagulants May Outweigh Risk of Bleeding in Patients With Atrial Fibrillation
Reinitiation of oral anticoagulant therapy may be warranted for some patients with atrial fibrillation who have a high risk of bleeding.
VWF High-Molecular-Weight Multimer Deficiency Associated With Neurological Symptoms in TTP
Researchers assessed whether loss of von Willebrand factor high-molecular-weight multimers was predictive of morbidity in thrombotic thrombocytopenic purpura.
A Patient-Centered Model of Congenital Thrombotic Thrombocytopenic Purpura Symptoms and Effects
Researchers interviewed clinicians and patients to develop a conceptual model of congenital thrombotic thrombocytopenic purpura.
Revisiting Guidelines on the Use of Direct Oral Anticoagulants in Obese Patients With Atrial Fibrillation
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Evans Syndrome: Incidence, Prevalence, and Survival
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
Direct Oral Anticoagulants Show Similar Efficacy Compared With Warfarin in Morbidly Obese Patients
Incidences of recurrent thromboembolism and major bleeding did not significantly differ between patients receiving DOACs and patients receiving warfarin.
A New Standard of Care for Immune-Mediated Thrombotic Thrombocytopenic Purpura?
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
Underlying Connective Tissue Disorders in TTP Result in Longer, More Expensive Hospitalizations
A higher proportion of black patients and female patients with thrombotic thrombocytopenic purpura had coexisting connective tissue disorders.
Want to read more?
Please login or register first to view this content.
Next post in Thrombotic Disorders
